Abstract:Background: Inflammatory bowel disease (IBD) constitutes a group of auto-inflammatory disorders that impact the gastrointestinal tract and other systemic organs. The gut microbiome contributes to IBD pathology through multiple mechanisms. Bacteriophages (hereafter termed phages) are viruses that are able to specifically infect bacteria. Considered as part of the gut microbiome, phages may impact the bacterial community structure in various clinical contexts. Additionally, exogenous phage administration may represent a means of suppressing IBD-associated pathobionts; however, the utilization of phage therapy remains at an early developmental phase. Objectives: Herein, we summarize the latest advances in understanding endogenous phage impacts on the gut microbiome in a healthy gut and in IBD. We highlight the prospect of phage utilization as a targeted mode of pathobiont eradication, for preventing and treating IBD manifestations and complications. Sources: Selected peer-reviewed publications regarding the role of phages in a healthy gut and in IBD, published between 2013 and 2022. Content: The human gut microbiome is increasingly suggested to play a significant role in the onset and progression of multiple non-communicable diseases such as IBD. Several studies suggest that this effect may be mediated by discrete disease-contributing commensals. However, the eradication of such pathogenic bacteria remains a daunting unmet task. Altered community structure in IBD may be influenced by blooms of phages within the gut bacterial ecosystem. Moreover, combinations of phages specifically targeting disease-contributing pathobiont strain clades may be harnessed as potential eradication treatment preventing and treating IBD, while bearing minimal adverse impacts on the surrounding bacterial microbiome. Implications: Understanding the endogenous phage-gut commensal interactions in a healthy gut and in IBD may enable phage utilization in precision gut microbiome editing, towards treating IBD and other non-communicable microbiome-associated diseases. Nevertheless, developing phage combination-mediated IBD pathobiont eradication treatment modalities will likely necessitate better strain-level bacterial target identification and resolution of treatment-related challenges, such as phage delivery, off-target effects, and bacterial resistance.

A theoretical model of temperate phages as mediators of gut microbiome dysbiosis

Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease

Phages in the Gut Ecosystem

Gut phageome: challenges in research and impact on human microbiota

Dietary Effects on the Gut Phageome

The human gut phageome: composition, development, and alterations in disease

The gut virome and the relevance of temperate phages in human health

Microbiome-phage interactions in inflammatory bowel disease

The Presence of Bacteriophages in the Human Body: Good, Bad or Neutral?

Gut Phageome—An Insight into the Role and Impact of Gut Microbiome and Their Correlation with Mammal Health and Diseases

Role of bacteriophages in shaping gut microbial community

Phage therapy in gut microbiome

Phage as signatures of healthy microbiomes

Phage Therapy in Gastrointestinal Diseases

Intricate Crosstalk Between Food Allergens, Phages, Bacteria, and Eukaryotic Host Cells of the Gut-skin Axis

Bacteriophage-mediated modulation of microbiota for diseases treatment

Bacteriophages and their potential for treatment of gastrointestinal diseases

The relationship between the phageome and human health: are bacteriophages beneficial or harmful microbes?

Prophage induction contributes to alterations in the gut phageome during intestinal inflammation

Bacteriophage-mediated manipulation of the gut microbiome - promises and presents limitations

Factors Affecting Variation of the Human Gut Phageome